LJPC La Jolla Pharmaceutical Company

34.62
+0.43  (1%)
Previous Close 34.19
Open 34.41
Price To book 6.78
Market Cap 766668313
Shares 22,145,243
Volume 5,416
Short Ratio 16.02
Av. Daily Volume 251,174

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Pivotal trial to be initiated 2H 2017.
LJPC-401
Beta thalassemia patients suffering from iron overload
Phase 3 data released February 27, 2016 - primary endpoint hit. Data published May 21, 2017 confirmed primary endpoint was met but with lack of mortality improvement. PDUFA date under priority review February 28, 2018. No Advisory Committee Meeting planned.
LJPC-501
Hypotension

Latest News

  1. La Jolla Pharmaceutical Co. breached its 50 day moving average in a Bearish Manner : LJPC-US : November 20, 2017
  2. La Jolla Pharmaceutical Co. breached its 50 day moving average in a Bullish Manner : LJPC-US : November 8, 2017
  3. La Jolla Pharmaceutical Earns Relative Strength Rating Upgrade
  4. La Jolla Pharmaceutical posts 3Q loss
  5. La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2017 and Recent Corporate Progress
  6. La Jolla Pharmaceutical Co. – Value Analysis (NASDAQ:LJPC) : October 26, 2017
  7. La Jolla Pharmaceutical Co. breached its 50 day moving average in a Bearish Manner : LJPC-US : October 25, 2017
  8. Featured Company News - La Jolla Pharma Announces Intent to Submit MAA for LJPC-501, or Angiotensin II
  9. La Jolla Pharmaceutical Company Announces Intent to Submit Marketing Authorization Application for LJPC-501 in the Third Quarter of 2018
  10. Prespecified Analysis of ATHOS-3 Indicates Survival Benefit in LJPC-501-Treated Patients with Relatively Low Angiotensin II State
  11. La Jolla Pharmaceutical Co. breached its 50 day moving average in a Bearish Manner : LJPC-US : September 15, 2017
  12. La Jolla Pharmaceutical Company Announces U.S. FDA Acceptance of New Drug Application for LJPC-501
  13. La Jolla Pharmaceutical Co. breached its 50 day moving average in a Bullish Manner : LJPC-US : August 25, 2017
  14. Corporate News Blog - Insys Therapeutics Releases Statement on Illinois Settlement; Provides Data against the Opioid-Induced Calamity in the US
  15. La Jolla Pharmaceutical Co. – Value Analysis (NASDAQ:LJPC) : August 14, 2017
  16. La Jolla Pharmaceutical Co. breached its 50 day moving average in a Bearish Manner : LJPC-US : August 11, 2017
  17. La Jolla Pharmaceutical Company Announces Launch of Expanded Access Program for LJPC-501
  18. La Jolla Pharmaceutical Co. breached its 50 day moving average in a Bearish Manner : LJPC-US : July 31, 2017
  19. La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2017 and Recent Corporate Progress

SEC Filings

  1. 8-K - Current report 171160350
  2. S-3 - Registration statement under Securities Act of 1933 171160293
  3. S-8 - Securities to be offered to employees in employee benefit plans 171160270
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171157079
  5. SC 13G - Statement of acquisition of beneficial ownership by individuals 171129638
  6. 8-K - Current report 171111530
  7. 8-K - Current report 171071429
  8. 8-K - Current report 171058323
  9. DEF 14A - Other definitive proxy statements 17991207
  10. 8-K - Current report 17986923